Inhibition of erythrocyte binding of PvTRAg33.5 derived fragments and peptides by <i>P. vivax</i> patients’ sera.

<p>Pooled <i>P. vivax</i> infected patients’ sera (<b>A</b>) and by purified anti-PvTRAg33.5 antibodies from these pooled patients sera (<b>B</b>) were used for these antibody mediated inhibition assays. The tagged recombinant PvTRAg33.5, its fragments, or synthetic peptides were mixed with different dilutions of <i>P.vivax</i> patients’ sera or purified antibodies before adding to the microtiter plate coated with one million erythrocytes. Further steps of color development were same as in Fig. 1 and 2B. Binding in the absence of antibody is taken as percentage control. Error bar indicates the standard deviation of mean from three experiments. No Ab, no antibody; HCS, healthy human control sera.